54 In another phase 2 trial done to evaluate the efficacy of orforglipron in adults with obesity without diabetes, it was found to lead to significant weight reduction compared to placebo
Blue Cross Blue Shield evaluates eligibility for weight loss surgery based on a combination of factors, including the severity of obesity, the presence of obesity-related comorbidities, and the failure of traditional weight loss methods
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
doi: 10.1016/j.ejphar.2021.174510 254 ShraimBAMoursiMOBenterIFHabibAMAkhtarS
Technical specifications for the Alpha-MSH C-terminal tripeptide fragment
Greco, Esmeralda Capristo, Giuseppe Benedetti, Annalisa Giancaterini, Andrea De Gaetano, and Giovanni Gasbarrini (1999)